PPARG and alcoholic fatty liver disease: The PPARγ agonist rosiglitazone has been shown to exert anti-ferroptotic effects in non-alcoholic fatty liver disease models, suggesting that modulation of the PPARγ pathway may be a promising therapeutic strategy [35,36,37].